In Brief: Biomira/Neoprobe Corp.
This article was originally published in The Gray Sheet
Executive Summary
Biomira/Neoprobe Corp.: Firms ink agreement under which Neoprobe gains exclusive worldwide rights to use Biomira's radiolabeled urine monoclonal antibody Mab-170 in its RIGS hand-held, gamma-detecting probe technology "for surgical detection of breast cancer." Neoprobe plans to commence Phase I trials with the MAb-170/RIGS device with up to 45 women undergoing breast-conserving surgery. In return, Biomira receives an upfront fee from Neoprobe, as well as milestone payments and royalties "upon commercialization of a RIGS product using MAb-170." Under the deal, Neoprobe also obtains rights to: the MAb-170/RIGS technology for other clinical indications; any enhancements to the MAb-170 antibody; and an option to license another Biomira antibody, MAb-174...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.